Articles

Poll

Podcasts

Slideshows

Videos

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Alva outlines how general clinicians should address patient questions on psychedelic therapies, including risks, approvals, and referral pathways.


Guidance for Clinicians on Patient Questions About Psychedelics, With Gus Alva, MD

Alva discusses infrastructure gaps, training demands, and unmet psychiatric need amid accelerated policy momentum for psychedelic therapies.

Psychiatry Infrastructure Lags Psychedelic Momentum, With Gus Alva, MD

Following an April 18 executive order, Gus Alva, MD, discusses psychedelic mechanisms, evidence, and clinical considerations for psychiatry.

White House Order Accelerates Psychedelic Research for Mental Illness, With Gus Alva, MD

Explore the latest advancements in psychiatry, including FDA updates, emerging therapies, and promising clinical trial results for mental health treatments.

Q3 2025 Recap: Psychiatry News and Updates

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

5 Psychiatry Headlines You Missed in September 2025

MDMA’s CRL, now available to the public, cites gaps in safety data, selection bias, and limited durability.

FDA Releases CRL Detailing Safety Concerns for MDMA-Assisted Therapy in PTSD

Explore the transformative potential of MDMA-assisted therapy and psychedelics in treating PTSD and addiction, offering hope where traditional methods fail.

We Need to Be More Open to Psychedelic and Alternative Treatments

Transcend Therapeutics' TSND-201 gains FDA Breakthrough Therapy designation, offering new hope for rapid PTSD treatment with promising clinical trial results.

FDA Grants TSND-201 Breakthrough Therapy Designation for PTSD

At SLEEP 2025, Colvonen discussed RCT findings that showed VeNS significantly improved PTSD and insomnia symptoms, offering a scalable solution for patients awaiting 1-on-1 care.